Nektar Therapeutics (NKTR)

88.23
1.80 2.10
NASDAQ : Health Technology
Prev Close 86.45
Open 86.59
Day Low/High 86.59 / 90.96
52 Wk Low/High 12.50 / 99.02
Volume 2.38M
Avg Volume 2.47M
Exchange NASDAQ
Shares Outstanding 160.39M
Market Cap 13.38B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Stocks finished higher on Wednesday.

Nektar Shares Surge on Bristol-Myers Collaboration

Nektar Shares Surge on Bristol-Myers Collaboration

Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar's lead...

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

It is premature to think that this market has hit a top until there is further evidence in the price action.

Next Week Could Be Confusing

Many summer winners are in correction mode.

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.

New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline To Be Presented At The 2017 Society For Immunotherapy Of Cancer 32nd Annual Meeting

New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline To Be Presented At The 2017 Society For Immunotherapy Of Cancer 32nd Annual Meeting

Company to host Investor & Analyst Event on Saturday, November 11th following an oral presentation of data from PIVOT Phase 1/2 study of NKTR-214 with nivolumab

Nektar Therapeutics Announces Seven Abstracts Accepted For Presentation At 2017 Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting

Nektar Therapeutics Announces Seven Abstracts Accepted For Presentation At 2017 Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting

Clinical Data for NKTR-214 in Combination with Nivolumab Accepted for Oral Presentation (PIVOT-02 Study)

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

IntelliPharmaceuticals has a bio-equivalent to OxyContin, but says it is harder to tamper with. The pharma company is hoping to gain a recommendation from an FDA committee on Wednesday.

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

NKTR-181 is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.

Nektar Announces Topline Data From Human Abuse Potential Study For NKTR-181, A First-in-Class Investigational Opioid To Treat Chronic Pain

Nektar Announces Topline Data From Human Abuse Potential Study For NKTR-181, A First-in-Class Investigational Opioid To Treat Chronic Pain

NKTR-181 shows significantly less abuse potential compared to oxycodone

TheStreet Quant Rating: D- (Sell)